Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Biopharma, Inc. on January 10, 2022, covering events occurring on January 4, 2022. The Company, incorporated in Delaware with principal offices in Australia, entered into a material definitive agreement to secure financing.
Key Financial Metrics and Transaction Details
- Debt Instrument: Convertible Promissory Note with a principal amount of $63,750.
- Net Proceeds: $60,000 (after deducting $3,750 in fees and expenses).
- Interest Rate: 8% per annum, payable in cash or shares of common stock upon maturity or acceleration.
- Maturity Date: October 21, 2022.
- Conversion Terms: Convertible at the investor's option starting July 3, 2022, at a price equal to 65% of the Market Price (a 35% discount).
- Liquidity Use: Proceeds designated for general working capital purposes.
Material Changes and Terms
The filing discloses the creation of a direct financial obligation. Key terms include:
- Prepayment Penalties: The Note may be prepaid within 180 days of issuance, subject to escalating premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment.
- Default Provisions: Upon certain events of default, the outstanding principal may increase to 150% or 200% of the face amount. A penalty of $1,000 per day applies if shares are not delivered within three business days of a conversion notice.
- Covenants: The Company is restricted from selling substantially all assets without consent and must maintain listing on an OTC market or equivalent exchange.
Outlook, Risks, and Contingencies
The transaction was executed as a private placement under Section 4(a)(2) of the Securities Act. Significant risks identified in the filing include:
- Dilution Risk: The 35% discount on the conversion price and the potential for interest to be paid in shares may result in significant dilution to existing shareholders.
- Default Risk: Failure to meet reporting requirements, maintain stock listing, or timely issue shares upon conversion triggers severe financial penalties and acceleration of debt.
- Ownership Cap: The investor is restricted from converting if it would cause their beneficial ownership to exceed 4.99% of outstanding shares.
Investor Verification Checklist
- Verify the Company's current cash position and ability to service the 8% interest or convert to equity without immediate liquidity strain.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Note (Exhibit 4.1) for specific definitions of "Market Price" and "Trading Day."
- Confirm the Company's compliance with ongoing SEC reporting requirements to avoid triggering default events related to reporting failures.
- Assess the potential dilution impact on existing shareholders given the 35% discount conversion feature.